Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death in First-Line Treatment for HER2-positive Advanced or Metastatic Breast Cancer By Ogkologos - November 3, 2025 128 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Breast09 study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Pembrolizumab to Include Neoadjuvant... March 13, 2024 What to Know About At-Home DNA Tests for Detecting Cancer Risk May 24, 2022 European Lung Cancer Virtual Congress 2021, 25-27 March [Event Announcement] March 12, 2021 FDA Approves Fruquintinib for Patients with Refractory Metastatic Colorectal Cancer November 20, 2023 Load more HOT NEWS Keto Molecule Offers Clue for Preventing Colorectal Cancer How People With Advanced Cancer Can Find Meaning Toward the End... Androgen Receptor May Explain Sex Differences in Melanoma Treatment Response How We’re Working to Build a Cancer Survivorship Community: Survivors’ Perspectives
